2/4 #BladderCancer at #ESMO26 🟢 #VOLGA — LBA2 - Positive EFS/OS topline announced for durva + EV. Looking for the magnitude of benefit, surgical outcomes, and toxicity. - We know EV+IO has led to major improvements in outcomes for MIBC. Can we offer a less toxic perioperative paradigm with omission of post-op EV? 🟡 #KEYNOTEB15 ctDNA — 4734O - Molecular response with perioperative EV + pembrolizumab in MIBC. - Can #ctDNA identify residual risk beyond what we learn from surgical pathology? - Particularly interested in discordant results. Identifying a favorable-risk group is different from proving we can safely reduce treatment. @myESMO @OncoAlert @oncodaily @OncoDailyGU @urotoday @GUOncologyNow